The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
Open accessAbstract
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit sustained at 4 years. We report updated 5-year efficacy and biomarker findings. Patients and Methods: Patients with resected stage IIIB–C/IV melanoma were stratified by stage and baseline programmed death cell ligand 1 (PD-L1) expression and received nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks, both intravenously for 1 year until disease recurrence, unacceptable toxicity, or withdrawal of consent. The primary endpoint was RFS. Results: At a minimum follow-up of 62 months, RFS with nivolumab remained superior to ipilimumab (HR = 0.72; 95% confidence interval, 0.60–0.86; 5-year rates of 50% vs. 39%). Five-year distant metastasis-free survival (DMFS) rates were 58% with nivolumab versus 51% with ipilimumab. Five-year overall survival (OS) rates were 76% with nivolumab and 72% with ipilimumab (75% data maturity: 228 of 302 planned events). Higher levels of tumor mutational burden (TMB), tumor PD-L1, intratumoral CD8+ T cells and IFNγ-associated gene expression signature, and lower levels of peripheral serum C-reactive protein were associated with improved RFS and OS with both nivolumab and ipilimumab, albeit with limited clinically meaningful predictive value. Conclusions: Nivolumab is a proven adjuvant treatment for resected melanoma at high risk of recurrence, with sustained, long-term improvement in RFS and DMFS compared with ipilimumab and high OS rates. Identification of additional biomarkers is needed to better predict treatment outcome. See related commentary by Augustin and Luke, p. 3253
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Self-citationAdjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Self-citationAscierto, P. A., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30494-0 · Cited by 537
Self-citationTarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01381 · Cited by 184
Cited by
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Blank, C. U., Lucas, M. W., Scolyer, R. A., van de Wiel, B. A., Menzies, A. M., Lopez-Yurda, M., Hoeijmakers, L. L., Saw, R. P. M., Lijnsvelt, J. M., Maher, N. G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402604 · Cited by 542
Self-citationExosome-based immunotherapy as an innovative therapeutic approach in melanoma
Babaei, S., Fadaee, M., Abbasi-kenarsari, H., Shanehbandi, D., & Kazemi, T. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01906-1 · Cited by 48
Metadata
- Authors
- Larkin, J., Del Vecchio, M., Mandalá, M., Gogas, H., Arance Fernandez, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., Middleton, M. R., Lutzky, J., de la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A. G., Fecher, L. A., Millward, M., Nathan, P. D., Khushalani, N. I., Queirolo, P., Ritchings, C., Lobo, M., Askelson, M., Tang, H., Dolfi, S., Ascierto, P. A., & Weber, J.
- Venue
- Clinical Cancer Research
- Published
- 2023-04-14
- Volume
- 29
- Issue
- 17
- Pages
- 3352-3361
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W4365504267
- Cited by
- 198
- References
- 6
- FWCI
- 20.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-3145
- The paper
- Larkin, J., Del Vecchio, M., Mandalá, M., Gogas, H., Arance Fernandez, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., Middleton, M. R., Lutzky, J., de la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A. G., . . . Weber, J. (2023). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-3145
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.